Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2002 | Original Article

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

Authors: Christopher W. Ryan, Everett E. Vokes, Nicholas J. Vogelzang, Linda Janisch, Ken Kobayashi, Mark J. Ratain

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002

Title: A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
Authors: Christopher W. Ryan
Everett E. Vokes
Nicholas J. Vogelzang
Linda Janisch
Ken Kobayashi
Mark J. Ratain
Publication date: 01-07-2002
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-002-0458-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2002

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Suicide gene therapy using E. coli β-galactosidase

Pilot study of gemcitabine (10 mg/m2 per min) and cisplatin

Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia

Rapid biotransformation of satraplatin by human red blood cells in vitro

The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer